Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2018

01-03-2018 | Adis Drug Evaluation

Landiolol: A Review in Tachyarrhythmias

Author: Yahiya Y. Syed

Published in: Drugs | Issue 3/2018

Login to get access

Abstract

Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol has been demonstrated in a large number of randomized controlled clinical trials. Landiolol significantly reduced heart rate in patients with postoperative or intraoperative supraventricular tachycardia relative to placebo and in those with atrial fibrillation/flutter and left ventricular dysfunction relative to digoxin. It was more effective than diltiazem in converting postoperative atrial fibrillation (POAF) to normal sinus rhythm. Perioperative prophylactic administration of landiolol significantly reduced the incidence of POAF during the first week after cardiac and other surgeries, compared with diltiazem, placebo or no landiolol treatment. Landiolol also attenuated adverse haemodynamic and other responses to invasive procedures such as percutaneous coronary intervention, tracheal intubation, extubation and electroconvulsive therapy. Landiolol was generally well tolerated, with a relatively low risk of hypotension and bradycardia. Landiolol has more favourable pharmacological properties than esmolol, a short-acting β-blocker commonly used for the rapid control of heart rate. Although additional comparative studies are warranted to define the place of landiolol relative to esmolol, current evidence suggest that landiolol is a useful option for the rapid short-term control of tachyarrhythmias. Landiolol offers a simple dosage scheme and is available in two easy-to-use formulations (concentrate and powder).
Literature
1.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975.CrossRefPubMed
2.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefPubMed
3.
Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(18):1493–531.CrossRefPubMed
4.
5.
6.
Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73(9):959–77.CrossRefPubMed
7.
Taenaka N, Kikawa S. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2013;13(5):353–64.CrossRefPubMedPubMedCentral
8.
Mori K, Yamada K, Fukuda T, et al. Landiolol hydrochloride for early postoperative tachycardia after transthoracic esophagectomy. Surg Today. 2014;44(5):848–54.CrossRefPubMed
9.
Niwa Y, Koike M, Iwata N, et al. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. Hepatogastroenterology. 2014;61(134):1546–51.PubMed
10.
Hamaguchi S, Nagao M, Takahashi Y, et al. Low dose landiolol combined with catecholamine can decrease heart rate without suppression of cardiac contraction after cardiopulmonary bypass. Dokkyo J Med Sci. 2014;41(1):27–33.
11.
Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J. 2012;76(5):1097–101.CrossRefPubMed
12.
Nishi H, Sakaguchi T, Miyagawa S, et al. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. Heart Vessels. 2013;28(4):490–6.CrossRefPubMed
13.
Ojima T, Iwahashi M, Nakamori M, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44(5):839–47.CrossRefPubMed
14.
Nojiri T, Yamamoto K, Maeda H, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011;59(12):799–805.CrossRefPubMed
15.
Shibata SC, Uchiyama A, Ohta N, et al. Efficacy and safety of landiolol compared to amiodarone for the management of postoperative atrial fibrillation in intensive care patients. J Cardiothorac Vasc Anesth. 2016;30(2):418–22.CrossRefPubMed
16.
Xiao J, He P, Zou Q, et al. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Anesth. 2015;27(2):120–8.CrossRefPubMed
17.
Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908–16.CrossRefPubMed
18.
Kinugawa K, Nagai R, Inoue H, et al. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: subgroup analysis of the J-Land study. Adv Ther. 2014;31(4):426–39.CrossRefPubMedPubMedCentral
19.
Kobayashi S, Murakami W, Myoren T, et al. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology. 2014;127(2):105–13.CrossRefPubMed
20.
Ozaki T, Yamada T, Morita T, et al. Urgent control of rapid atrial fibrillation using landiolol in patients with acute decompensated heart failure with reduced or preserved left ventricular ejection fraction [abstract no. P6352]. Eur Heart J. 2016;37(Suppl.):1319.
21.
Kobayashi S, Susa T, Tanaka T, et al. Low-dose beta-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J Off J Jpn Circ Soc. 2012;76(7):1646–53.
22.
Adachi T, Sato A, Baba M, et al. Novel use of the ultra-short-acting intravenous beta1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels. 2014;29(4):464–9.CrossRefPubMed
23.
Kobayashi S, Susa T, Ishiguchi H, et al. A low-dose β1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulum. PLoS One. 2015. https://​doi.​org/​10.​1371/​journal.​pone.​0114314.
24.
Kimura Y, Aga C, Hayashi H, et al. Efficacy and safety of landiolol in heart failure patients with supraventricular tachycardia compared to diltiazem [abstract no. O01-3]. J Card Fail. 2016;22(9 Suppl. 1):167.CrossRef
25.
Kiuchi S, Aikawa H, Hisatake S, et al. Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. J Clin Med Res. 2017;9(5):426–32.CrossRefPubMedPubMedCentral
26.
Wada Y, Aiba T, Tsujita Y, et al. Practical applicability of landiolol, an ultra-short-acting beta1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythm. 2016;32(2):82–8.CrossRefPubMed
27.
Oka E, Iwasaki Y, Fujimoto Y. Differential effectiveness of landiolol among atrial fibrillation and atrial flutter/tachycardia in the patients with left ventricular dysfunction [abstract no. PE-776]. In: In: 81st Annual Scientific Meeting of the Japanese Circulation Society. 2017.
28.
Yoshima S. Concomitant administration of landiolol and dobutamine in acute heart failure syndrome with atrial tachyarrhythmia [abstract no. P2699]. Eur Heart J. 2017; 38(Suppl).
29.
Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting beta1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015;4(3):251–7.CrossRefPubMedPubMedCentral
30.
Sezai A, Osaka S, Yaoita H, et al. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial. J Thorac Cardiovasc Surg. 2015;150(4):957–64.CrossRefPubMed
31.
Nagaoka E, Arai H, Tamura K, et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2014;20(2):129–34.CrossRefPubMed
32.
Ogawa S, Okawa Y, Goto Y, et al. Perioperative use of a beta blocker in coronary artery bypass grafting. Asian Cardiovasc Thorac Ann. 2013;21(3):265–9.CrossRefPubMed
33.
Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg. 2012;53(3):369–74.
34.
Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141(6):1478–87.CrossRefPubMed
35.
Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144(5):1241–8.CrossRefPubMed
36.
Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53(6):359–63.CrossRefPubMed
37.
Tamura T, Yatabe T, Yokoyama M. Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: a systematic review and meta-analysis. J Clin Anesth. 2017;42:1–6.CrossRefPubMed
38.
Ji T, Feng C, Sun L, et al. Are beta-blockers effective for preventing post-coronary artery bypass grafting atrial fibrillation? Direct and network meta-analyses. Ir J Med Sci. 2016;185(2):503–11.CrossRefPubMed
39.
Yoshida T, Furukita Y, Yamamoto Y, et al. A randomized, open label study of the efficacy of prophylactic 24-h low-dose landiolol for atrial fibrillation in transthoracic esophagectomy. Esophagus. 2017;14(1):97–103.CrossRef
40.
Ojima T, Nakamori M, Nakamura M, et al. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017;104(8):1003–9.CrossRefPubMed
41.
Horikoshi Y, Goyagi T, Kudo R, et al. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth. 2017;38:111–6.CrossRefPubMed
42.
Yagi K, Usuda J, Sakamoto A. Perioperative landiolol infusion reduces the incidence of atrial fibrillation after pulmonary lobectomy: postoperative randomized controlled study. Open J Anesthesiol. 2016;6:119–23.CrossRef
43.
Suzuki K, Numaguchi A, Adachi YU, et al. Continuous administration of landiolol reduced QT dispersion in postoperative patients. J Clin Anesth. 2014;26(6):438–42.CrossRefPubMed
44.
Kiyokuni M, Konishi M, Sakamaki K, et al. Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction. Int J Cardiol. 2016;221:321–6.CrossRefPubMed
45.
Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2013;167(4):1547–51.CrossRefPubMed
46.
Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–45.CrossRefPubMed
47.
Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–6.CrossRefPubMed
48.
Kawaguchi M, Kawaraguchi Y, Yamamoto Y, et al. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. J Anesth. 2010;24(4):503–10.CrossRefPubMed
49.
Miyazaki M, Kadoi Y, Takashi S, et al. Comparative effects of propofol, landiolol, and nicardipine on hemodynamic and bispectral index responses to endotracheal intubation: a prospective, randomized, double-blinded study. J Clin Anesth. 2008;24(4):257–62.CrossRef
50.
Kawaguchi M, Takamatsu I, Masui K, et al. Effect of landiolol on bispectral index and spectral entropy responses to tracheal intubation during propofol anaesthesia. Br J Anaesth. 2008;101(2):273–8.CrossRefPubMed
51.
Goyagi T, Tanaka M, Nishikawa T. Landiolol attenuates the cardiovascular response to tracheal intubation. J Anesth. 2005;19(4):282–6.CrossRefPubMed
52.
Oda Y, Nishikawa K, Hase I, et al. The short-acting β1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. Anesth Analg. 2005;100(3):733–7.CrossRefPubMed
53.
Wajima Z, Shiga T, Imanaga K, et al. Prophylactic continuous administration of landiolol, a novel β1 blocker, blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity. Int J Psychiatry Clin Pract. 2010;14(2):132–6.CrossRefPubMed
54.
Kitamura A, Sakamoto A, Inoue T, et al. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol. 1997;51(6):467–71.CrossRefPubMed
55.
Inoue S, Tanaka Y, Kawaguchi M, et al. The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review. Anaesth Intensive Care. 2009;37(6):893–902.PubMed
56.
Kaneko M, Yamaguchi S, Hamaguchi S, et al. Effects of landiolol on QT interval and QT dispersion during induction of anesthesia using computerized measurement. J Clin Anesth. 2009;21(8):555–61.CrossRefPubMed
57.
Yang X, Li S. Analysis of esmolol and landiolol on elderly patients in the perioperative period with gastric surgery. Int J Clin Exp Pathol. 2016;9(12):12755–60.
58.
Tochikubo J, Adachi YU, Ejima T, et al. Landiolol reduces hemodynamic responses to bronchoscopy-assisted suctioning in intubated ICU patients. J Intensive Care. 2014;2(6):1–4.
59.
Hirota K, Baba S, Fukushi S, et al. Efficacy of landiolol in attenuating hemodynamic responses to local epinephrine infiltration in patients undergoing vaginal total hysterectomy. J Anesth. 2005;19(1):17–20.CrossRefPubMed
60.
Saito S, Nishihara F, Akihiro T, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52(10):1027–34.CrossRefPubMed
61.
Krumpl G, Ulc I, Trebs M, et al. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73(4):417–28.CrossRefPubMed
62.
63.
Walter E, Schalle K. Cost-effectiveness of landiolol, an ultra-short-acting beta-blocker, for prevention of postoperative atrial fibrillation in Germany [abstract no. PCV84]. Value Heath. 2017;20(9).
64.
Nasrollahi-Shirazi S, Sucic S, Yang Q, et al. A comparison of the β-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359(1):73–81.CrossRefPubMed
65.
Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–6.CrossRefPubMed
66.
Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–65.CrossRefPubMed
67.
Sasao J, Tarver SD, Kindscher JD, et al. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anesth. 2001;48(10):985–9.CrossRefPubMed
68.
Krumpl G, Ulc I, Trebs M, et al. Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose landiolol during long-term infusion in Whites. J Cardiovasc Pharmacol. 2017;70(1):42–51.CrossRefPubMed
69.
Krumpl G, Ulc I, Trebs M, et al. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016;92:64–73.CrossRefPubMed
Metadata
Title
Landiolol: A Review in Tachyarrhythmias
Author
Yahiya Y. Syed
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0883-9

Other articles of this Issue 3/2018

Drugs 3/2018 Go to the issue

Adis Drug Evaluation

Eculizumab: A Review in Generalized Myasthenia Gravis

Leading Article

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy

Review Article

Prevention and Treatment of Chronic Postsurgical Pain: A Narrative Review

Correction

Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Adis Drug Evaluation

Belimumab: A Review in Systemic Lupus Erythematosus

Review Article

Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults